Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.

Li Y, Liang Z, Qin L, Wang M, Wang X, Zhang H, Liu Y, Li Y, Jia Z, Liu L, Zhang H, Luo J, Dong S, Guo J, Zhu H, Li S, Zheng H, Liu L, Wu Y, Zhong Y, Qiu M, Han Y, Stone GW

Open source

DOI: 10.1016/s0140-6736(22)01999-7
Published: 2022 Nov 26
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-22-01999-7,
  title = {Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.},
  author = {Li Y and Liang Z and Qin L and Wang M and Wang X and Zhang H and Liu Y and Li Y and Jia Z and Liu L and Zhang H and Luo J and Dong S and Guo J and Zhu H and Li S and Zheng H and Liu L and Wu Y and Zhong Y and Qiu M and Han Y and Stone GW},
  year = {2022},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(22)01999-7},
  url = {https://doi.org/10.1016/s0140-6736(22)01999-7}
}

RIS

TY  - JOUR
TI  - Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
AU  - Li Y
AU  - Liang Z
AU  - Qin L
AU  - Wang M
AU  - Wang X
AU  - Zhang H
AU  - Liu Y
AU  - Li Y
AU  - Jia Z
AU  - Liu L
AU  - Zhang H
AU  - Luo J
AU  - Dong S
AU  - Guo J
AU  - Zhu H
AU  - Li S
AU  - Zheng H
AU  - Liu L
AU  - Wu Y
AU  - Zhong Y
AU  - Qiu M
AU  - Han Y
AU  - Stone GW
PY  - 2022
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(22)01999-7
UR  - https://doi.org/10.1016/s0140-6736(22)01999-7
ER  -

APA

Y, L., Z, L., L, Q., M, W., X, W., H, Z., Y, L., Y, L., Z, J., L, L., H, Z., J, L., S, D., J, G., H, Z., S, L., H, Z., L, L., Y, W., Y, Z., M, Q., Y, H., & GW, S. (2022). Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(22)01999-7

Source records

pubmed · retrieved 2026-09-26T20:28:30.320Z